Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Cancer Chemotherapy and Pharmacology|March 19, 2008
Preclinical discovery of ixabepilone, a highly active antineoplastic agentFrancis Y F Lee, Robert Borzilleri, Craig R Fairchild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer modelsJennifer K Peterson, Chandra Tucker, Edward Favours, et al.
Cancer Chemotherapy and Pharmacology|March 20, 2008
Preclinical efficacy spectrum and pharmacokinetics of ixabepiloneFrancis Y F Lee, Richard Smykla, Kathy Johnston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2008
Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor modelsFrancis Y F Lee, Kelly L Covello, Stephen Castaneda, et al.
Organic Letters|February 26, 2003
SAR and pH stability of cyano-substituted epothilonesAlicia Regueiro-Ren, Kenneth Leavitt, Soong-Hoon Kim, et al.
Cancer Immunology Research|January 12, 2017
Dasatinib Changes Immune Cell Profiles Concomitant with Reduced Tumor Growth in Several Murine Solid Tumor ModelsCan Hekim, Mette Ilander, Jun Yan, et al.
Cancer Research|June 3, 2006
The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutantsJohn S Tokarski, John A Newitt, Chieh Ying J Chang, et al.
Cancer Research|June 3, 2004
Apoptotic and cytostatic farnesyltransferase inhibitors have distinct pharmacology and efficacy profiles in tumor modelsVeeraswamy Manne, Francis Y F Lee, David K Bol, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2008
Metabolism and disposition of dasatinib after oral administration to humansLisa J Christopher, Donghui Cui, Chiyuan Wu, et al.
Blood|May 15, 2008
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemiaKimmo Porkka, Perttu Koskenvesa, Tuija Lundán, et al.
Pageof 2